Patents Examined by Jeffrey S. Lundgren
  • Fatty acids as anti-inflammatory agents
    Patent number: 11723897
    Abstract: Compounds of formula I and their metabolites are potent mediators of an inflammatory response: where a, b, c, d, e, f, V, W, X, Y, Ra, Ra?, Rb, Rb?, Rc, and Rc? are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: August 15, 2023
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Methods and compositions for the treatment of cancer
    Patent number: 11717573
    Abstract: Disclosed herein are compositions for treating cancer comprising a modified veratridine. In certain aspects, the modified veratridine comprises a polyglutamic acid (PLE) or polyethylene glycol/polyglutamic acid (PEG-PLE) conjugated to the 4? hemiketal thereof. Further disclosed is a method of treating colorectal cancer in a subject comprising administering to a subject an effective amount of the disclosed compositions.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: August 8, 2023
    Assignee: South Dakota Board of Regents
    Inventors: Khosrow Rezvani, Grigoriy Sereda
  • Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment
    Patent number: 11718645
    Abstract: The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: August 8, 2023
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Hendrik Luesch, Qi-Yin Chen
  • Inhibitors of lysyl oxidases
    Patent number: 11712437
    Abstract: Described herein are novel compounds that block the activity of LOX family members having good IC50 values, no cellular toxicity below 10 ?M, induce sensitization of the cells to doxorubicin, strong activity in a recombinant LOX/LOXL2 activity, and a chemical structure that is drug-like and does not have a PAINS flag, as well as, methods of treatment using the compounds with respect to cancer, organ fibrosis, neurodegenerative and cardiovascular diseases.
    Type: Grant
    Filed: March 13, 2022
    Date of Patent: August 1, 2023
    Assignee: University of South Carolina
    Inventors: Ozgur Sahin, Campbell McInnes, Ozge Saatci, Chad Beneker, Abdol-Hossein Rezaeian, Metin Cetin
  • GLS1 inhibitors for treating disease
    Patent number: 11713313
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: August 1, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard Thomas Lewis, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Matthew Hamilton, Michael J. Soth, Timothy Heffernan, Michelle Han, Jason P. Burke
  • Antibacterial and antifungal compounds
    Patent number: 11707442
    Abstract: The present application provides that synthetic retinoid compounds are useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. faecalis, E. faecium, B. subtilis, and B. anthracis. The present application also provides a tricyclic fluoroquinolone compound, Z3060, useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. spp., K. pneumoniae, P. aeruginosa, A. baumannii, E. faecium, and E. faecalis. Also provided herein is a gold compound, auranofin, useful in treating bacterial and fungal infections, such as a fungal infection caused by C. albicans, C. parapsilosis, C. tropicalis, C. glabrata, and C. neoformans.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: July 25, 2023
    Assignees: The General Hospital Corporation, Rhode Island Hospital, A Lifespan-Partner
    Inventors: Helen Burgwyn Fuchs, Eleftherios Mylonakis, Frederick M. Ausubel, Raj Mohan Raja Muthiah, Wooseong Kim
  • Combination therapies for the treatment of cancer
    Patent number: 11707448
    Abstract: The present invention provides methods and compositions for treating cancer by administering an EP4 antagonist in combination with radiation therapy, antibody therapy and/or anti-metabolite chemotherapy.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: July 25, 2023
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Xingfeng Bao, Diana Albu, Mary Woodall-Jappe
  • Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
    Patent number: 11690832
    Abstract: The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: July 4, 2023
    Assignee: IO Therapeutics
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
    Patent number: 11690831
    Abstract: The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: July 4, 2023
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors
    Patent number: 11691973
    Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.
    Type: Grant
    Filed: December 1, 2022
    Date of Patent: July 4, 2023
    Assignee: Pfizer Inc.
    Inventors: Shelley Allen, Patrick Michael Doerner Barbour, James Francis Blake, Sydney Taylor Blanche, Mark Laurence Boys, Wesley Dewitt Clark, Connor James Cowdrey, Joshua Ryan Dahlke, Alex Andrew Kellum, Ellen Margaret Knapp, David Austin Moreno, Jacob Matthew O'Leary, Li Ren, Faith Elizabeth Witkos, Jennifer Lynn Fulton
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 11680048
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: June 20, 2023
    Assignee: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Method for inhibiting virus infection and replication
    Patent number: 11679102
    Abstract: Disclosed herein is a method for inhibiting virus infection, including administering to a subject in need thereof an effective amount of a ferroptosis inhibitor or a pharmaceutically acceptable salt thereof. Also disclosed is a method for inhibiting viral replication, including contacting a virus with a ferroptosis inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: June 20, 2023
    Assignee: Chang Gung University
    Inventors: Shin-Ru Shih, Yu-An Kung, Huan-Jung Chiang, Chuan-Tien Hung, Yu-Nong Gong, Hsin-Ping Chiu, Chiung-Guei Huang, Peng-Nien Huang, Sheng-Yu Huang
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 11680047
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: June 20, 2023
    Assignee: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend
  • Method of reducing anxiety in non-human mammals by increasing brain serotonin levels
    Patent number: 11666553
    Abstract: A method of reducing anxiety in a non-human mammal by increasing brain serotonin levels, includes: down regulating in vivo levels of indigenous inflammatory cytokines in the nasal cavity of said non-human mammal by delivering an effective amount of an anti-inflammatory formula to said nasal cavity, which formula includes: at least one lipid-soluble antioxidant (which also functions as an anti-inflammatory agent) (the lipid-soluble antioxidant may be selected from the group consisting of alpha lipoic acid, aloe vera, omega 3 oil, N-acetylcysteine, cannabidiol, civet, oxytocin and combinations thereof); melatonin; tryptophan; and at least one essential oil. The most preferred antioxidant is N-acetylcysteine and the preferred essential oil is combination of chamomile, lavender and lemon oil.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: June 6, 2023
    Assignee: NORTH CELL PHARMCETICALS INC.
    Inventor: Alain Martin
  • Hair growth composition and method
    Patent number: 11666520
    Abstract: The present invention relates to compositions for and methods of retarding hair loss or facilitating hair growth comprising a hair growth active, a mixture of C12-C15 alkyl lactates and a viscosity modifying agent comprising at least one cellulose and/or a cellulose derivative. Clear compositions are also disclosed.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: June 6, 2023
    Assignee: Johnson & Johnson Consumer Inc.
    Inventor: Jeffrey M. Wu
  • Treatment of polycystic diseases with an HDAC6 inhibitor
    Patent number: 11666569
    Abstract: An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and ?-catenin phosphorylation and/or acetylation while reducing bile duct ?-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 6, 2023
    Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) U.S. GOVERNMENT
    Inventors: Sergio A. Gradilone, Nicholas F. LaRusso
  • Compounds and their use
    Patent number: 11667602
    Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: June 6, 2023
    Assignees: AstraZeneca AB, MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kenneth Lars Granberg, Shigeki Sakamaki, Ryuichi Fuchigami, Yasuki Niwa, Masakazu Fujio, Hans Fredrik Bergström, Stig Jonas Boström
  • Calcium BOPTA complex
    Patent number: 11667601
    Abstract: The present invention relates to the calcium complex of (4RS)(4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl oxa-5,8,11-triazatridecan-13-oato(5-))pentahydrogen (BOPTA) in the form of a salt, to the process for its preparation and to a formulation comprising said salt.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: June 6, 2023
    Assignee: BRACCO IMAGING S.P.A.
    Inventors: Andrea Banin, Laura Galimberti, Roberta Napolitano, Roberta Fretta
  • Oral GSNOR inhibitor and pharmaceutical use thereof
    Patent number: 11667616
    Abstract: Disclosed are a thiazolone derivative of N6022 and a pharmaceutical use thereof. The characteristic structure of the thiazolone derivative of N6022 is: Compared to N6022, the compound of the present disclosure has good oral bioavailability and a longer half-life period. In in-vitro experiments, administering the compound of the present disclosure can improve migration ability, tube formation ability and, the permeability of human umbilical vein endothelial cells caused by high glucose, and administering the compound of the present disclosure at an animal level can obviously promote the angiogenesis and blood flow recovery of ischemic lateral limbs of diabetic mice. Overall, it suggests that the compound of the present disclosure can be used for treating diseases related to diabetic vascular complications.
    Type: Grant
    Filed: April 25, 2021
    Date of Patent: June 6, 2023
    Assignee: NANJING MEDICAL UNIVERSITY
    Inventors: Yong Ji, Liping Xie, Shuang Zhao, Tianyu Song, Yi Han
  • Method of maintaining oral health in animals
    Patent number: 11660300
    Abstract: Use of a compound having the formula (I) in the manufacture of a medicament for the prevention or treatment of a disease caused by oral bacteria in an animal wherein R1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or 3-position of the morpholino ring, and R2 is a straight or branched alkyl group containing 2 to 10 carbon atoms, substituted with a hydroxy group except in the alpha-position, or a pharmaceutically acceptable salt thereof. A cosmetic method of preventing or decreasing oral staining in an animal, comprising the step of exposing the oral cavity to a morpholino compound of general.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: May 30, 2023
    Inventors: Hugo De Bruyn, Rolf Valter Attstrom